Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 4, 2021 Category: Internal Medicine Tags: Hematology-Oncology News Source Type: news
EIT Health invests €3M in innovations for endometrial cancer and Parkinson's disease
The Wild Card open innovation programme has selected two innovator teams from Spain and Germany. (Source: mobihealthnews)
Source: mobihealthnews - February 1, 2021 Category: Information Technology Source Type: news
New, simplified genetic test effectively screens for hereditary cancers
(Elsevier) Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of DNA in colon, endometrial, and other cancers. This alternative to complex, multi-step testing workflows can also determine causes of MMR deficiency often missed by current clinical tests. Their results are presented in The Journal of Molecular Diagnostics, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news
Oral Contraceptives Tied to Lower Risk for Certain Cancers
The drugs may increase the risk of breast cancer, but may lower the risk of ovarian and endometrial cancers. (Source: NYT Health)
Source: NYT Health - January 5, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Ovarian Cancer Breast Cancer Women and Girls Deaths (Fatalities) Birth Control and Family Planning Source Type: news
Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
MONDAY, Dec. 21, 2020 -- Oral contraceptives have a lasting protective effect against ovarian and endometrial cancer, according to a study published online Dec. 17 in Cancer Research.
Torgny Karlsson, Ph.D., from Uppsala University in Sweden, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news
Oral contraceptive pills protect against ovarian and endometrial cancer
(Uppsala University) A comprehensive study from Uppsala University, involving more than 250,000 women, shows that oral contraceptive use protects against ovarian and endometrial cancer. The protective effect remains for several decades after discontinuing the use. The study is published in the journal Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news
Two-Drug Combo Standard of Care in Advanced Endometrial Cancer Two-Drug Combo Standard of Care in Advanced Endometrial Cancer
Survival outcomes for the combination paclitaxel-carboplatin were similar to those with paclitaxel, doxorubicin, and cisplatin but with lower toxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FES-PET could predict endometrial cancer outcomes
PET imaging with the radiotracer F-18 fluoroestradiol (FES) can help determine...Read more on AuntMinnie.comRelated Reading:
Imaging agent for breast cancer PET gets FDA nod
FES-PET enhances treatment for metastatic breast cancer
FES-PET detects estrogen-receptor-positive breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 7, 2020 Category: Radiology Source Type: news
Constitutive expression of progesterone receptor isoforms promotes the development of hormone-dependent ovarian neoplasms
Differences in the relative abundances of the progesterone receptor (PGR) isoforms PGRA and PGRB are often observed in women with reproductive tract cancers. To assess the importance of the PGR isoform ratio in the maintenance of the reproductive tract, we generated mice that overexpress PGRA or PGRB in all PGR-positive tissues. Whereas few PGRA-overexpressing mice developed reproductive tract tumors, all PGRB-overexpressing mice developed ovarian neoplasms that were derived from ovarian luteal cells. Transcriptomic analyses of the ovarian tumors from PGRB-overexpressing mice revealed enhanced AKT signaling and a gene expr...
Source: Signal Transduction Knowledge Environment - October 5, 2020 Category: Science Authors: Wetendorf, M., Li, R., Wu, S.-P., Liu, J., Creighton, C. J., Wang, T., Janardhan, K. S., Willson, C. J., Lanz, R. B., Murphy, B. D., Lydon, J. P., DeMayo, F. J. Tags: STKE Research Articles Source Type: news
Mayo Clinic Q and A: Understanding endometrial cancer
DEAR MAYO CLINIC: My 54-year-old sister was diagnosed recently with early-stage endometrial cancer. She only went to the doctor because she had bleeding between menstrual cycles. I'm wondering if I am at risk, too, and if there is anything I can do to reduce my risk. Is there a screening test? ANSWER: An increased risk for endometrial [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 29, 2020 Category: Databases & Libraries Source Type: news
Women's Wellness: Obesity increases endometrial cancer risk
Endometrial cancer, which begins in the uterus within the layer of cells that form the uterine lining, has been on the rise over the past decade. Each year in the U.S., over 60,000 women are diagnosed with endometrial cancer, also referred to as uterine cancer. Endometrial cancer is now the most common cancer to affect [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 16, 2020 Category: Databases & Libraries Source Type: news
Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news
Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news
